Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology.

Kinase inhibitors are at the forefront of modern drug research, where mostly three technologies are used for hit-and-lead finding: high throughput screening of random libraries, three-dimensional structure-based drug design based on X-ray data, and focused libraries around limited number of new cores. Our novel Nested Chemical Library (NCL) (Vichem Chemie Research Ltd., Budapest, Hungary) technology is based on a knowledge base approach, where focused libraries around selected cores are used to generate pharmacophore models. NCL was designed on the platform of a diverse kinase inhibitory library organized around 97 core structures. We have established a unique, proprietary kinase inhibitory chemistry around these core structures with small focused sublibraries around each core. All the compounds in our NCL library are stored in a big unified Structured Query Language database along with their measured and calculated physicochemical and ADME/toxicity (ADMET) properties, together with thousands of molecular descriptors calculated for each compound. Biochemical kinase inhibitory assays on selected, cloned kinase enzymes for a few hundred NCL compound sets can provide sufficient biological data for rational computerized design of new analogues, based on our pharmacophore model-generating 3DNET4W QSPAR (quantitative structure-property/activity relationships) approach. Using this pharmacophore modeling approach and the ADMET filters, we can preselect synthesizable compounds for hit-and-lead optimization. Starting from this point and integrating the information from QSPAR, high-quality leads can be generated within a small number of optimization cycles. Applying NCL technology we have developed lead compounds for several validated kinase targets.

[1]  C. Bevan,et al.  Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC:  A High-Throughput Alternative to log P/log D. , 1997, Analytical chemistry.

[2]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[3]  G. Kéri,et al.  Improved, high yield synthesis of 3H-quinazolin-4-ones, the key intermediates of recently developed drugs. , 2004, Current Medicinal Chemistry.

[4]  R. Huber,et al.  Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. , 2003, Structure.

[5]  A. Levitzki,et al.  Signal-transduction therapy. A novel approach to disease management. , 1994, European journal of biochemistry.

[6]  László Orfi,et al.  Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods. , 2004, Mini reviews in medicinal chemistry.

[7]  I Kövesdi,et al.  Reliability of logP predictions based on calculated molecular descriptors: a critical review. , 2002, Current medicinal chemistry.

[8]  Christopher S. Poss,et al.  Novel CCR1 antagonists with improved metabolic stability. , 2004, Bioorganic & medicinal chemistry letters.

[9]  A. Mathiowetz,et al.  Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor. , 2003, Biochemical and biophysical research communications.

[10]  J. Goldman.  Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia , 2000, The Lancet.

[11]  G. Kéri,et al.  Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. , 2005, Bioorganic & medicinal chemistry letters.

[12]  G. Mcmahon,et al.  Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. , 1996, Journal of medicinal chemistry.

[13]  Ola Engkvist,et al.  Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. , 2004, Chemistry & biology.

[14]  G. Kéri,et al.  New antitumor leads from a peptidomimetic library , 1999, Letters in Peptide Science.

[15]  J. Cherrington,et al.  Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor , 2004, Oncogene.

[16]  A. Ullrich,et al.  Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. , 2005, Cancer research.

[17]  D. J. Calderwood,et al.  Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight. , 2002, Bioorganic & medicinal chemistry letters.

[18]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[19]  J. Cherrington,et al.  Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents , 2003, Expert opinion on investigational drugs.

[20]  György Kéri,et al.  Cellular targets of gefitinib. , 2005, Cancer research.

[21]  G. Kéri,et al.  Pro‐Apoptotic and Anti‐Apoptotic Molecules Affecting Pathways of Signal Transduction , 2003, Annals of the New York Academy of Sciences.

[22]  P. Beroza,et al.  Chemoproteomics as a basis for post-genomic drug discovery. , 2002, Drug discovery today.

[23]  S. Zanetti,et al.  Quinoxalin-2-ones. Part 5. Synthesis and antimicrobial evaluation of 3-alkyl-, 3-halomethyl- and 3-carboxyethylquinoxaline-2-ones variously substituted on the benzo-moiety. , 2003, Farmaco.

[24]  A. Ullrich,et al.  Flk-1 as a target for tumor growth inhibition. , 1996, Cancer research.

[25]  M. Myers,et al.  Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and effective bioisosteric replacement of a phenyl substituent. , 2003, Bioorganic & medicinal chemistry letters.

[26]  S. Hazeldine,et al.  Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). , 2001, Journal of medicinal chemistry.

[27]  B. Klebl.  Chemical kinomics - a target gene family approach in chemical biology. , 2004, Drug discovery today. Technologies.

[28]  G. Scapin.  Structural biology in drug design: selective protein kinase inhibitors. , 2002, Drug discovery today.

[29]  G. Kéri,et al.  Cytostatic, cytotoxic and protein tyrosine kinase inhibitory activity of ursolic acid in A431 human tumor cells. , 2000, Anticancer research.

[30]  M. Myers,et al.  Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: the synthesis and biological activities of RPR127963 an orally bioavailable inhibitor. , 2003, Bioorganic & medicinal chemistry letters.